NanoVibronix UroShield Products Available On NHS Drug Tariff Effective November 1
Portfolio Pulse from Benzinga Newsdesk
NanoVibronix, Inc. (Nasdaq: NAOV) announced that its UroShield actuators are eligible for reimbursement on NHS Prescription Services' Drug Tariff effective November 1. The company has received a stocking order from its U.K. distribution partner, Peak Medical Limited, in anticipation of increased demand. The Drug Tariff provides for full reimbursement of UroShield actuators by the NHS, allowing clinicians to prescribe the products.
November 07, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NanoVibronix's UroShield products are now eligible for NHS reimbursement, which is expected to increase demand and revenues. The company has received a stocking order from its UK partner, Peak Medical Limited.
The news of NHS reimbursement eligibility for NanoVibronix's UroShield products is likely to increase demand and revenues for the company. This is further confirmed by the stocking order received from its UK partner, Peak Medical Limited. This is directly relevant to NanoVibronix and is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100